Rakovina Therapeutics Inc. RKV.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · rakovinatherapeutics.com
Rakovina Therapeutics Inc. is a biopharmaceutical research company engaged in developing cancer treatments targeting DNA-damage response systems. The company's pipeline includes the kt-2000 series (oral PARP inhibitors), kt-3000 series (dual PARP/HDAC inhibitors), kt-4000 series (targeted DNA damage inducers), and kt-5000 series (brain-penetrant dual ATR-mTOR inhibitors), leveraging AI platforms to accelerate drug discovery. The company is headquartered in Vancouver, Canada.
Key ratios
ReturnOnAssets TTM -0.93
ReturnOnAssets 2024 -0.42
ReturnOnAssets 2023 -0.28
ReturnOnAssets 2022 -0.24
ReturnOnEquity TTM -3.34
ReturnOnEquity 2024 -1.02
ReturnOnEquity 2023 -0.54
ReturnOnEquity 2022 -0.38
Recent news
Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update
2026-06-01 · GlobeNewswire
Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update
2026-04-30 · GlobeNewswire
Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting
2026-04-22 · GlobeNewswire